Pharmacokinetics and safety of a novel CFTR corrector molecule GLPG2222 in subjects with cystic fibrosis (CF): Results from a phase Ib study

Authors
Category Primary study
JournalJournal of Cystic Fibrosis
Year 2017
This article has no abstract
Epistemonikos ID: 3dff96bc50f83fbf6fba68c3e7c62112bc946638
First added on: Feb 08, 2025